⚕ GalenOps CRO console
← SITE005 (FRA)

SITE005-0139

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE005 (FRA) (Dr. Muller) · consented 2022-08-09
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

severe assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-23 (study day 3); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 40); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 40); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-06 (study day 47); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 121); relationship: N

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 145); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 198); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 202); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-17 (study day 209); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.